Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial

Braeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint.

Risperidone, the most commonly-prescribed therapy for schizophrenia, depends on consistent administration, but patients with schizophrenia sometimes stop taking their medication when their symptoms improve. Long-acting, injectable formulations of risperidone are on the market, but there is no FDA-approved formulation that lasts for 6-months, according to Braeburn.

Get the full story at our sister site, Drug Delivery Business News.

The post Braeburn’s risperidone implant meets primary endpoint in schizophrenia trial appeared first on MassDevice.

from MassDevice http://ift.tt/2plPm9b